Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurovascular Effects of AC Chemotherapy in Breast Cancer
NCT04568161Completed
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegylated liposomal doxorubicin and cyclophosphamide in breast cancer, sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoint: Muscle Sympathetic Nerve Activity. Started Aug 2020; status: completed.
02
Drugs
pegylated liposomal doxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04568161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568161.